<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205864</url>
  </required_header>
  <id_info>
    <org_study_id>KIA 2019/93</org_study_id>
    <nct_id>NCT04205864</nct_id>
  </id_info>
  <brief_title>Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.</brief_title>
  <official_title>Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel
      matrix used and not used during pelvic lymph node dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic lymph node dissection is the most accurate staging tool to determine lymph node
      involvement in endometrial cancer. Lymphoceles developed after surgery can cause serious
      morbidity, additional costs and delays in chemotherapy or radiotherapy. In this study,
      conventional pelvic lymphadenectomy will be compared with thrombin gel matrix application
      after pelvic lymphadenectomy. Our goal is to prospectively assess the lymphostatic effect of
      thrombin gel matrix in endometrial cancer patients undergoing pelvic lymph node dissection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">July 2, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Application of Thrombin gel matrix after Pelvic lymphadenectomy. And compare this application with Conventional Pelvic Lymphadenectomy.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of pelvic lymphocele</measure>
    <time_frame>post-operative 2th month</time_frame>
    <description>Frequency pelvic lymphocele at post-operative 2th month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of radiographic lymphoceles</measure>
    <time_frame>post-operative 2th month</time_frame>
    <description>Volume of lymphocele detected with radiographic imagining at post-operative 2th month (the two largest dimensions measured in centimetres)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of postoperative drainage catheter</measure>
    <time_frame>up to post-operative 1 week</time_frame>
    <description>duration of postoperative drainage catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative drain amount (ml: milliliters)</measure>
    <time_frame>with 1 weeks after surgery</time_frame>
    <description>Postoperative drain amount (ml: milliliters)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Lymphocele</condition>
  <condition>Lymphocele After Surgical Procedure</condition>
  <condition>Endometrium Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional pelvic lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional pelvic lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrombin gel matrix pelvic lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thrombin gel matrix applicated after conventional pelvic lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thrombi-Gel</intervention_name>
    <description>Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy</description>
    <arm_group_label>Thrombin gel matrix pelvic lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Pelvic lymphadenectomy</intervention_name>
    <description>Conventional Pelvic lymphadenectomy</description>
    <arm_group_label>Conventional pelvic lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endometrial cancer patients who need laparotomic bilateral PLND

          -  Patients suitable for surgery

        Exclusion Criteria:

          -  Previous pelvic surgery

          -  Previous Chemotherapy or Radiotherapy

          -  Patients who undergo only lymph node sampling

          -  Patients who have not signed Informed Consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Şener Gezer, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kocaeli University</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Kim YH, Shin HJ, Ju W, Kim SC. Prevention of lymphocele by using gelatin-thrombin matrix as a tissue sealant after pelvic lymphadenectomy in patients with gynecologic cancers: a prospective randomized controlled study. J Gynecol Oncol. 2017 May;28(3):e37. doi: 10.3802/jgo.2017.28.e37. Epub 2017 Feb 28.</citation>
    <PMID>28382800</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Şener Gezer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Lymphocele</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

